Overview
Zeng Wang practices practicing medicine in Hangzhou, China.
Their clinical expertise encompasses Small Cell Lung Cancer (SCLC), Triple-Negative Breast Cancer, Lung Cancer, and PIK3CA-Related Overgrowth Spectrum.
They are actively involved in clinical research, co-authoring 11 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Zeng Wang
Is Zeng Wang a top-rated expert for Small Cell Lung Cancer (SCLC)?
MediFind is an objective health platform that identifies experts based on real-world data. Zeng Wang is classified as an Experienced expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Zeng Wang participate in research or clinical trials?
Yes. Zeng Wang has published 11 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Zeng Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Lung AdenocarcinomaWang isExperienced. Learn about Lung Adenocarcinoma.
- Lung CancerWang isExperienced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- PIK3CA-Related Overgrowth Spectrum
- Small Cell Lung Cancer (SCLC)
- Triple-Negative Breast Cancer